Cargando…

Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.

The effect of clodronate on bone mineral density (BMD) was studied in 121 post-menopausal breast cancer women without skeletal metastases. In addition, two antioestrogens, tamoxifen and toremifene, were compared in their action on bone mineral density. Patients were randomized to have an adjuvant an...

Descripción completa

Detalles Bibliográficos
Autores principales: Saarto, T., Blomqvist, C., Välimäki, M., Mäkelä, P., Sarna, S., Elomaa, I.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group|1 1997
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063321/
https://www.ncbi.nlm.nih.gov/pubmed/9052418
_version_ 1782137312373637120
author Saarto, T.
Blomqvist, C.
Välimäki, M.
Mäkelä, P.
Sarna, S.
Elomaa, I.
author_facet Saarto, T.
Blomqvist, C.
Välimäki, M.
Mäkelä, P.
Sarna, S.
Elomaa, I.
author_sort Saarto, T.
collection PubMed
description The effect of clodronate on bone mineral density (BMD) was studied in 121 post-menopausal breast cancer women without skeletal metastases. In addition, two antioestrogens, tamoxifen and toremifene, were compared in their action on bone mineral density. Patients were randomized to have an adjuvant antioestrogen treatment either 20 mg of tamoxifen or 60 mg of toremifene daily for 3 years. In addition all patients were randomized to have 1600 mg of oral clodronate daily or to act as control subjects. BMD of the lumbar spine and femoral neck were measured by dual-energy radiographic absorptiometry before therapy and at 1 and 2 years. At 2 years, clodronate with antioestrogens markedly increased BMD in the lumbar spine and femoral neck by 2.9% and 3.7% (P = 0.001 and 0.006 respectively). There were no significant changes in BMD in the patients given antioestrogens only. No significant differences were found between tamoxifen and toremifene on bone mineral density. Clodronate with antioestrogens significantly increased bone mass in the lumbar spine and femoral neck. Both antioestrogens, tamoxifen and toremifene, similarly prevented bone loss in the lumbar spine and femoral neck.
format Text
id pubmed-2063321
institution National Center for Biotechnology Information
language English
publishDate 1997
publisher Nature Publishing Group|1
record_format MEDLINE/PubMed
spelling pubmed-20633212009-09-10 Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Saarto, T. Blomqvist, C. Välimäki, M. Mäkelä, P. Sarna, S. Elomaa, I. Br J Cancer Research Article The effect of clodronate on bone mineral density (BMD) was studied in 121 post-menopausal breast cancer women without skeletal metastases. In addition, two antioestrogens, tamoxifen and toremifene, were compared in their action on bone mineral density. Patients were randomized to have an adjuvant antioestrogen treatment either 20 mg of tamoxifen or 60 mg of toremifene daily for 3 years. In addition all patients were randomized to have 1600 mg of oral clodronate daily or to act as control subjects. BMD of the lumbar spine and femoral neck were measured by dual-energy radiographic absorptiometry before therapy and at 1 and 2 years. At 2 years, clodronate with antioestrogens markedly increased BMD in the lumbar spine and femoral neck by 2.9% and 3.7% (P = 0.001 and 0.006 respectively). There were no significant changes in BMD in the patients given antioestrogens only. No significant differences were found between tamoxifen and toremifene on bone mineral density. Clodronate with antioestrogens significantly increased bone mass in the lumbar spine and femoral neck. Both antioestrogens, tamoxifen and toremifene, similarly prevented bone loss in the lumbar spine and femoral neck. Nature Publishing Group|1 1997 /pmc/articles/PMC2063321/ /pubmed/9052418 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Saarto, T.
Blomqvist, C.
Välimäki, M.
Mäkelä, P.
Sarna, S.
Elomaa, I.
Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
title Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
title_full Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
title_fullStr Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
title_full_unstemmed Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
title_short Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
title_sort clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063321/
https://www.ncbi.nlm.nih.gov/pubmed/9052418
work_keys_str_mv AT saartot clodronateimprovesbonemineraldensityinpostmenopausalbreastcancerpatientstreatedwithadjuvantantioestrogens
AT blomqvistc clodronateimprovesbonemineraldensityinpostmenopausalbreastcancerpatientstreatedwithadjuvantantioestrogens
AT valimakim clodronateimprovesbonemineraldensityinpostmenopausalbreastcancerpatientstreatedwithadjuvantantioestrogens
AT makelap clodronateimprovesbonemineraldensityinpostmenopausalbreastcancerpatientstreatedwithadjuvantantioestrogens
AT sarnas clodronateimprovesbonemineraldensityinpostmenopausalbreastcancerpatientstreatedwithadjuvantantioestrogens
AT elomaai clodronateimprovesbonemineraldensityinpostmenopausalbreastcancerpatientstreatedwithadjuvantantioestrogens